课题基金 / 基金详情

Planning Grant: I/UCRC for technology innovation for novel cost-reducing and quality-enhancing musculoskeletal therapies

Planning Grant: I/UCRC for technology innovation for novel cost-reducing and quality-enhancing musculoskeletal therapies
规划补助金:I/UCRC 用于新型降低成本和提高质量的肌肉骨骼疗法的技术创新
批准号:
1265896
负责人:
Jeffrey Lotz
金额:
$3.84万
依托单位国家:
美国
项目类别:
Standard Grant
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-01-01 至 2014-05-31

项目摘要

项目成果

Jeffrey Lotz的其他基金

相似基金

相关文献

中文摘要
翻译
1265896加州大学旧金山分校(加州大学旧金山分校);Jeffrey Lotz拟建的中心将专注于与肌肉骨骼护理的几个领域相关的技术进步和健康结果、质量和成本的趋势,包括脊柱、关节置换和运动医学。加州大学旧金山分校(UCSF)、托莱多大学(UT)和加州大学伯克利分校(UCB)正在合作建立拟议的中心,加州大学旧金山分校是牵头机构。随着当前医疗改革的趋势,控制医疗成本的需要与国家致力于技术创新以改善人类健康之间的冲突越来越大。因此,成功的医疗开发现在不仅包括推进安全有效的新技术,还包括考虑护理、定价和报销的总体成本。颠覆性创新是节省成本的新技术,或者通过改善结果和/或降低成本来增加医疗保健方面的价值。成功开发颠覆性肌肉骨骼创新需要平衡临床洞察力、技术诀窍、供应链管理和商业市场情报。拟议的活动涉及实质性工程和生物工程多学科合作。商业教师的参与为工程系统的挑战提供了一个坚实的途径,使创新疗法的价值最大化。拟议的中心将代表着医疗保健经济学、生物医学科学和临床医学的令人兴奋和新颖的整合,因为我们的目标是为肌肉骨骼疾病患者的管理削减成本和提高质量的干预措施的技术创新。拟议的中心将侧重于多学科研究活动的自然融合,从而为在所支持的研究活动期间接受指导的受训者提供丰富的教育经验。该中心计划实施一项积极的方案,以确定和纳入来自代表性不足群体的中心成员和受训人员。重要的数据和发现将通过中心网站和中心支持的研究成果出版物进行传播和共享。
英文摘要
1265896 University of California-San Francisco (UCSF); Jeffrey Lotz The proposed center will focus on technological advances and trends of health outcomes, quality, and costs associated with several areas of musculoskeletal care, including spine, arthroplasty, and sports medicine. University of California, San Francisco (UCSF), the University of Toledo (UT), and the University of California-Berkeley (UCB) are collaborating to establish the proposed center, with UCSF as the lead institution. With current trends in healthcare reform, there is a growing conflict between the need for medical cost containment and the nation's commitment to technological innovation to improve human health. Consequently, successful medical therapy development now includes not only advancing new technologies that are safe and effective, but also factoring overall costs for the episode of care, pricing, and reimbursement. Disruptive innovations are new technologies that are cost-saving, or that add value to the healthcare encounter by improving outcome and/or reducing cost. Success in developing disruptive musculoskeletal innovations requires balancing clinical insight, technological know-how, supply chain management, and commercial market intelligence. The proposed activity involves substantial engineering and bio-engineering multi-disciplinary collaboration. Business faculty involvement provides a solid approach to the engineering systems challenge of maximizing the value of innovative therapies. The proposed Center will represent an exciting and novel integration of healthcare economics, biomedical science, and clinical medicine as we target technological innovations on cost-cutting and quality-enhancing interventions for management of patients with musculoskeletal disease. The proposed Center will focus on a natural integration of multi-disciplinary research activities, and consequently, a cross-fertilization that provides rich educational experiences for trainees who are mentored during the supported research activities. The Center plans to implement an active program for identifying and including Center members and trainees from underrepresented groups. Important data and findings will be disseminated and shared via the Center website and publications that result from Center-supported research.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Phase II IUCRC at UC San Francisco: Center for Disruptive Musculoskeletal Innovations (CDMI)
CDMI - FDA SMART Workshop
I/UCRC: Technology Innovation for Novel Cost-reducing and Quality-enhancing Musculoskeletal Therapies
海外基金